| DC7868 |
AS703026（Pimasertib）
Featured
|
AS703026(Pimasertib) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines. |
|
| DC7421 |
GO 6976
Featured
|
Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3. |
|
| DC10034 |
GLPG0187
Featured
|
GLPG0187 is a small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity. |
|
| DC11089 |
TAS-120 (Futibatinib)
Featured
|
TAS-120 is a highly potent and selective irreversible FGFR inhibitor, effective in tumors harboring various FGFR gene abnormalities. |
|
| DC26121 |
FOY-251 mesylate
Featured
|
FOY 251 is a metabolite of Camostat and a pollen protease inhibitor for prevention and control of allergy. |
|
| DC8860 |
Vorapaxar
Featured
|
Vorapaxar (SCH 530348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM. |
|
| DC9514 |
Deforolimus
Featured
|
Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin.
IC50 value: 0.2 nM [1]
Target: mTOR
in vitro: Treatment of HT |
|
| DCAPI1551 |
Tacalcitol
Featured
|
Tacalcitol is a synthetic vitamin D3 analog. This compound has been shown to regulate calcium levels and induce nerve growth factor production in epidermal keratinocytes. Additionally, Tacalcitol has been noted to promotes normal bone development by regul |
|
| DC10475 |
Grapiprant
Featured
|
Grapiprant is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2) |
|
| DC10320 |
Saroglitazar (Magnesium) |
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively. |
.gif)
|
| DC10322 |
Saroglitazar |
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively. |
|
| DC7666 |
MK0752
Featured
|
MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2. |
|
| DC10109 |
Q203
Featured
|
Q203 is a promising new clinical candidate for the treatment of tuberculosis. |
|
| DC11450 |
Selpercatinib(LOXO-292)
Featured
|
Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively. Antineoplastic activity. |
|
| DC8142 |
TAS-116
Featured
|
TAS-116 is a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. |
|
| DC8901 |
Azilsartan medoxomil
Featured
|
Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension. |
|
| DC5080 |
Belnacasan (VX-765)
Featured
|
VX-765 is a novel Caspase-1 inhibitor with an IC 50 of 0.8nM being investigated for the treatment of epilepsy, currently being developed by Vertex. |
|
| DC7622 |
BIBX1382
Featured
|
BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM). |
|
| DC26133 |
Camostat mesylate
Featured
|
Camostat mesylate is a synthetic, orally bioavailable is a serine protease inhibitor. Used for the treatment of chronic pancreatitis. It attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. |
|
| DC7163 |
ZLN005
Featured
|
ZLN005 is a novel transcriptional regulator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α). |
|
| DC7488 |
RO4987655
Featured
|
RO4987655(CH-4987655) is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1 IC50=5.2 nM), with potential antineoplastic activity. |
|
| DC7028 |
SB242235
Featured
|
SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM. |
|
| DC9873 |
Selonsertib（GS-4997）
Featured
|
Selonsertib（GS-4997）is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. |
|
| DC12355 |
Ceralifimod (ONO-4641) |
Ceralifimod is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC50s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively. |
|
| DC7694 |
BAF312 (Siponimod)
Featured
|
BAF312 is a potent and selective agonist of S1P with EC50 value of 0.39nM for S1P1 receptors and 0.98nM for S1P5 receptors, respectively |
|
| DC8598 |
PLK1 inhibitor GSK461364
Featured
|
GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM. |
|
| DC1076 |
Otenabant(CP945598.HCl)
Featured
|
CP-945598 HCl is a potent and selective cannabinoid type 1 receptor antagonist with Ki of 0.7 nM. |
|
| DC11735 |
Remdesivir(GS-5734)
Featured
|
Remdesivir is a novel RNA-dependent RNA Polymerase,(RdRp) inhibitor. The purity of remdesivir>99.8%,signal impurity<0.05%. |
|
| DC26208 |
Remdesivir metabolite(GS-441524)
Featured
|
Remdesivir metabolite.Remdesivir blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 Nm,and also showed potent activity blocking 2019-nCov(Coronavirus). |
|
| DC26230 |
Furin Inhibitor I
Featured
|
Furin inhibitor I is a selective, irreversible, and cell-permeable competitive inhibitor of proprotein convertases, including furin/SPC1 (Ki = ~1 nM), SPC2/PC2 (Ki = 0.36 nM), SPC3/PC1/PC3 (Ki = 2.0 nM), SPC4/PACE4 (Ki = 3.6 nM), SPC6/PC5/PC6, and SPC7/LP |
|
